Kalinox: Uses, Dosage & Side Effects
A premixed medicinal gas of 50% nitrous oxide and 50% oxygen for rapid short-term pain relief and anxiolysis during medical procedures
Kalinox is a premixed medicinal gas containing an equimolar mixture of 50% nitrous oxide (N2O) and 50% oxygen (O2), used for short-term analgesia and anxiolysis during painful medical procedures. Commonly known as "laughing gas" in its pure form, Kalinox provides rapid-onset pain relief within 3-5 minutes of inhalation, with effects wearing off within 5 minutes after stopping. It is widely used in emergency departments, labor and delivery suites, dental clinics, wound care settings, and pediatric units. The self-administered demand-valve system serves as an inherent safety mechanism, as patients who become excessively sedated naturally release the mask. Kalinox is approved for use in adults and children who can cooperate with the inhalation technique.
Quick Facts: Kalinox
Key Takeaways
- Kalinox is a 50/50 mixture of nitrous oxide and oxygen that provides rapid, short-acting pain relief and anxiety reduction during medical procedures
- Effects begin within 3-5 minutes and wear off within 5 minutes of stopping inhalation, allowing quick recovery
- Self-administration via demand valve acts as a built-in safety mechanism — if patients become too drowsy, they release the mask and the effect dissipates
- Widely used in emergency departments, obstetrics, pediatrics, wound care, and dental procedures across Europe and many other countries
- Should not be used in patients with pneumothorax, bowel obstruction, intracranial hypertension, or conditions where trapped gas expansion could be dangerous
What Is Kalinox and What Is It Used For?
Kalinox belongs to a class of medicinal gases known as inhaled analgesics. The product delivers a fixed equimolar mixture of nitrous oxide (N2O) and oxygen (O2) in equal proportions. Nitrous oxide has been used in medicine since the mid-19th century and remains one of the most widely employed inhaled analgesic agents in clinical practice today. The premixed formulation ensures that patients always receive a safe and consistent ratio, eliminating the risk of hypoxia that could occur with incorrectly mixed gases.
The primary mechanism of action involves activation of descending noradrenergic inhibitory pathways in the brainstem and release of endogenous opioid peptides, particularly in the periaqueductal gray area of the midbrain. Additionally, nitrous oxide acts as an antagonist at N-methyl-D-aspartate (NMDA) receptors and modulates gamma-aminobutyric acid type A (GABA-A) receptors. This combination of effects produces a dissociative analgesic state characterized by reduced pain perception, mild euphoria, and anxiolysis, while preserving consciousness and protective airway reflexes.
Kalinox is indicated for a wide range of clinical applications. In emergency departments, it is commonly used during wound suturing, fracture reduction, abscess drainage, burn dressing changes, and joint reduction procedures. In obstetric settings, it provides labor pain relief, particularly during contractions, and has been a mainstay of labor analgesia in countries such as the United Kingdom, Australia, Finland, and Sweden for decades. In pediatric medicine, Kalinox is especially valuable because it is non-invasive, has rapid onset and offset, and is well-tolerated by children who can cooperate with the inhalation technique.
Additional clinical uses include dental procedures (particularly for anxious patients or those undergoing extractions), minor surgical procedures performed under local anesthesia, diagnostic procedures such as lumbar punctures, bone marrow biopsies, and endoscopies, and wound care procedures in chronic wound management. Kalinox can also be used during transport of trauma patients to provide analgesia before reaching the hospital.
The 50% oxygen component of Kalinox is a significant advantage over other sedation methods, as it ensures that patients maintain adequate tissue oxygenation throughout the procedure. This is particularly important in trauma patients, elderly individuals, and those with borderline respiratory function. The fixed ratio also means that Kalinox can be safely administered by trained healthcare professionals who are not anesthesiologists, expanding access to effective procedural analgesia across healthcare settings.
What Should You Know Before Taking Kalinox?
Before Kalinox is administered, your healthcare provider will conduct a thorough assessment to ensure it is safe for you. While Kalinox has an excellent safety profile for short-term procedural use, several important contraindications and precautions must be considered. Understanding these factors helps ensure the safest possible experience during your procedure.
Contraindications
Kalinox must not be used in several specific clinical situations. Because nitrous oxide is more soluble in blood than nitrogen, it can diffuse into air-filled spaces faster than nitrogen can diffuse out, causing expansion of trapped gas. This property makes Kalinox absolutely contraindicated in patients with:
- Pneumothorax — trapped air in the chest cavity could expand, worsening respiratory compromise and potentially causing tension pneumothorax
- Air embolism — gas bubbles in the bloodstream could expand, increasing the risk of vascular obstruction
- Bowel obstruction — distended bowel loops containing trapped gas could expand further, increasing the risk of perforation
- Intracranial hypertension — gas expansion in intracranial air spaces (e.g., after cranial surgery or trauma) could dangerously increase intracranial pressure
- Maxillofacial injuries with suspected pneumocephalus — air in the cranial vault could expand
- Recent diving with decompression sickness risk — nitrogen bubbles in tissues could expand
- Recent intraocular gas injection — gas used in eye surgery (such as SF6 or C3F8) could expand, causing dangerous intraocular pressure increases
Kalinox should never be used in patients who cannot cooperate with self-administration (e.g., heavily sedated patients, infants, patients with altered consciousness), as the demand-valve safety mechanism requires active inhalation. Patients who have received sedative medications should be carefully assessed before Kalinox administration.
Warnings and Precautions
Special caution is required in several patient populations. Healthcare providers should exercise particular care when considering Kalinox for the following situations:
- Vitamin B12 deficiency or risk factors — Nitrous oxide irreversibly oxidizes cobalt in vitamin B12 (cobalamin), inactivating the enzyme methionine synthase. Repeated or prolonged exposure can cause megaloblastic anemia and subacute combined degeneration of the spinal cord. Patients with known or suspected B12 deficiency, vegans, and those with pernicious anemia require particular caution.
- Chronic obstructive pulmonary disease (COPD) — While the 50% oxygen component is beneficial, some patients with severe COPD and chronic CO2 retention may experience respiratory depression with high-flow oxygen. Clinical monitoring is essential.
- Middle ear conditions — Nitrous oxide can diffuse into the middle ear, increasing pressure and potentially causing discomfort or tympanic membrane rupture in patients with Eustachian tube dysfunction.
- Sinusitis — Gas expansion in blocked sinuses may cause pain.
- Head injuries — Without confirmed absence of intracranial air, use is contraindicated.
Occupational exposure is an important consideration for healthcare workers who regularly administer Kalinox. Chronic occupational exposure to nitrous oxide has been associated with reproductive toxicity, including increased risk of spontaneous abortion in early pregnancy, and neurological effects related to vitamin B12 inactivation. Adequate scavenging systems and room ventilation are essential when Kalinox is used regularly. Most regulatory bodies have established workplace exposure limits (typically 25-100 ppm as a time-weighted average over 8 hours) to protect healthcare workers.
Pregnancy and Breastfeeding
Kalinox is widely used during labor and delivery and has a long safety record in obstetric practice. Short-term use during labor has not been shown to cause adverse fetal effects. The gas crosses the placenta rapidly but is also eliminated rapidly through the lungs of both mother and neonate after birth. Apgar scores and neonatal outcomes are comparable to other methods of labor analgesia.
However, prolonged or repeated exposure during pregnancy (as opposed to single-use during labor) should be avoided due to the theoretical risk of vitamin B12 inactivation and potential teratogenic effects observed in animal studies with very high or prolonged exposures. Healthcare workers who are pregnant should minimize occupational exposure to nitrous oxide and ensure adequate workplace ventilation and gas scavenging systems are in place.
Nitrous oxide is eliminated rapidly through the lungs and does not accumulate in breast milk in clinically significant amounts. Breastfeeding can be resumed immediately after a Kalinox procedure with no waiting period required.
How Does Kalinox Interact with Other Drugs?
Because nitrous oxide acts on multiple receptor systems in the central nervous system, it can interact with other medications that affect CNS function. The most clinically significant interactions involve additive or synergistic sedation with other CNS-active drugs. While Kalinox alone has a wide safety margin due to the self-administration safety mechanism, combining it with other sedatives can potentially override this protection if patients are already partially sedated.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Significance |
|---|---|---|
| Opioids (morphine, fentanyl, codeine) | Additive CNS depression and respiratory depression | Monitor respiratory rate and sedation level closely; may need dose reduction of opioid |
| Benzodiazepines (midazolam, diazepam, lorazepam) | Enhanced sedation and anxiolysis; risk of excessive sedation | Increased risk of loss of airway protective reflexes; careful monitoring required |
| Methotrexate | Both drugs interfere with folate metabolism; compounded B12/folate depletion | Increased risk of megaloblastic anemia and myelosuppression; avoid in patients on high-dose methotrexate |
| Alcohol | Additive CNS depression | Intoxicated patients may have impaired self-administration safety mechanism |
Minor Interactions
| Drug / Drug Class | Interaction Effect | Clinical Significance |
|---|---|---|
| Antihistamines (diphenhydramine, promethazine) | Mild additive sedation | Usually clinically insignificant; routine monitoring sufficient |
| Antidepressants (SSRIs, TCAs) | Potential for mild additive CNS effects | No dosage adjustment typically required; standard monitoring |
| Bleomycin | High oxygen concentration (50%) may potentiate pulmonary toxicity | Theoretical concern; avoid if possible in patients with bleomycin-related lung damage |
| Local anesthetics (lidocaine, bupivacaine) | Additive analgesic effect (beneficial interaction) | Commonly used together for enhanced pain control; reduces local anesthetic requirement |
Unlike many drugs metabolized by liver enzymes (cytochrome P450 system), nitrous oxide is not metabolized in the body and is eliminated entirely through the lungs. This means it has no pharmacokinetic interactions — all interactions are pharmacodynamic (related to additive or opposing effects at receptor sites). This is a significant safety advantage compared to many other sedation agents.
What Is the Correct Dosage of Kalinox?
Unlike most medications, Kalinox does not require precise weight-based dosage calculations. The gas is delivered at a fixed concentration (50% nitrous oxide / 50% oxygen) and the patient self-regulates the amount inhaled through a demand-valve system. This self-titration approach is a fundamental safety feature: the patient must actively inhale to receive the gas, and if sedation becomes excessive, the patient naturally stops inhaling, allowing rapid recovery. A qualified healthcare professional must always be present during administration to monitor the patient and manage the delivery system.
Adults
Standard Adult Administration
- Pre-procedure: Begin inhalation 3-5 minutes before the painful stimulus to achieve adequate analgesic levels
- During procedure: Continue continuous inhalation throughout the procedure
- Post-procedure: Discontinue immediately after the procedure; recovery occurs within 5 minutes
- Maximum duration: Typically limited to 60 minutes of continuous use in a single session. Procedures lasting longer should be reassessed for alternative analgesia
- Frequency: Can be used for repeated procedures but should not be used more than 15 consecutive days due to risk of vitamin B12 inactivation
Children
Pediatric Administration
- Age requirement: The child must be old enough to understand instructions and cooperate with holding the mask or mouthpiece (typically from age 3-4 years, depending on developmental stage)
- Preparation: Allow the child to become familiar with the mask before the procedure. Use age-appropriate explanation and distraction techniques
- Administration: Same method as adults — self-administration via demand valve
- Supervision: Continuous observation by a healthcare professional trained in pediatric sedation is mandatory
- Duration: Same limits as adults; shorter procedures are preferred in pediatric patients
In pediatric emergency departments, Kalinox has been shown to be highly effective for procedures such as fracture reduction, wound closure, burn wound care, and intravenous cannulation in needle-phobic children. Studies demonstrate significantly reduced pain scores and procedure-related distress compared to placebo or no analgesic intervention.
Elderly
Geriatric Considerations
- Dosage: Same concentration and method as younger adults — no dose adjustment required for the gas concentration itself
- Enhanced monitoring: Elderly patients may be more sensitive to sedative effects and may have comorbidities requiring additional vigilance
- B12 status: Elderly patients have higher prevalence of vitamin B12 deficiency; consider checking B12 levels before repeated use
- Cognitive assessment: Patients with dementia or significant cognitive impairment may not be able to cooperate with self-administration
Missed Dose
The concept of a "missed dose" does not apply to Kalinox. It is used on-demand during procedures and is not a scheduled medication. If a procedure is postponed, Kalinox is simply administered at the rescheduled time. There is no need for catch-up dosing or adjustment.
Overdose
True overdose with self-administered Kalinox is extremely rare due to the built-in demand-valve safety mechanism. If a patient becomes excessively sedated, they naturally release the mask, stopping gas delivery. However, in cases where the gas is administered by continuous flow rather than demand valve, or where equipment malfunction occurs, potential overdose symptoms include:
- Deep sedation or loss of consciousness
- Respiratory depression
- Oxygen desaturation (though this is unlikely with the 50% O2 mixture)
- Nausea and vomiting with aspiration risk
Treatment: Immediately discontinue Kalinox and administer 100% oxygen. Maintain airway patency and support ventilation if needed. Recovery is typically rapid (within minutes) once the gas is stopped, as nitrous oxide is rapidly eliminated through the lungs.
What Are the Side Effects of Kalinox?
Kalinox is generally well tolerated, particularly when used for short-term procedural analgesia. Most adverse effects are mild, transient, and resolve spontaneously within minutes of discontinuing inhalation. The rapid elimination of nitrous oxide through the lungs means that side effects do not persist in the way they might with intravenously or orally administered sedatives.
The following frequency classification follows the international standard used by the European Medicines Agency (EMA) and the World Health Organization (WHO): Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (<1/1,000), Not known (frequency cannot be estimated from available data).
Very Common
Affects more than 1 in 10 patients
- Dizziness and light-headedness
- Euphoria ("floating" sensation)
- Nausea
Common
Affects 1 to 10 in 100 patients
- Vomiting
- Headache
- Paresthesia (tingling or numbness, especially in fingers and toes)
- Altered auditory perception (sounds seem distant or echoing)
- Drowsiness
- Fatigue
Uncommon
Affects 1 to 10 in 1,000 patients
- Anxiety or agitation (paradoxical reaction)
- Distorted visual perception
- Abdominal distension
- Middle ear pressure changes
- Excessive sedation
Rare
Affects fewer than 1 in 1,000 patients
- Diffusion hypoxia (transient oxygen desaturation immediately after stopping — preventable by administering supplemental oxygen for 3-5 minutes post-procedure)
- Allergic reactions
- Laryngospasm
Not Known (With Prolonged/Repeated Use)
Associated with prolonged or repeated exposure
- Vitamin B12 inactivation leading to megaloblastic anemia
- Subacute combined degeneration of the spinal cord (peripheral neuropathy, myelopathy)
- Leukopenia and immunosuppression
- Reproductive toxicity (associated with chronic occupational exposure)
The most serious concern with nitrous oxide is its ability to irreversibly oxidize vitamin B12, inactivating the enzyme methionine synthase. With single short-term procedural use, this effect is clinically insignificant. However, prolonged use (more than 6 consecutive hours), repeated frequent use (more than every 4 days), or use in patients with pre-existing B12 deficiency can lead to serious neurological complications including peripheral neuropathy, myelopathy, and encephalopathy. Patients who develop new-onset numbness, tingling, or weakness after Kalinox exposure should seek immediate medical evaluation. Blood tests for vitamin B12, methylmalonic acid, and homocysteine levels can confirm B12 functional deficiency.
The phenomenon of "diffusion hypoxia" deserves special mention. When Kalinox administration is stopped, the large volume of nitrous oxide rapidly diffusing out of the blood into the alveoli can temporarily dilute the alveolar oxygen concentration, causing a brief period of mild hypoxia. This is easily prevented by having the patient breathe supplemental oxygen or room air with deep breaths for 3-5 minutes after stopping the gas. In practice with the 50/50 mixture, clinically significant diffusion hypoxia is uncommon because the 50% oxygen component provides a substantial oxygen reserve.
How Should You Store Kalinox?
Proper storage of Kalinox cylinders is critical for patient safety. Unlike most medications stored in pharmacies or at home, Kalinox requires specific environmental conditions to maintain the correct gas mixture. Healthcare facilities must follow strict protocols for cylinder storage and handling.
Temperature requirements: Kalinox cylinders must be stored between -5°C and +45°C. This temperature range is crucial because at temperatures below -5°C, the nitrous oxide component can liquefy and separate from the oxygen, resulting in a non-homogeneous mixture. If a cylinder has been exposed to temperatures below -5°C, the initial gas delivered may be disproportionately high in oxygen while the later gas may be almost pure nitrous oxide, creating a dangerous hypoxic risk. Cylinders that have been stored in cold conditions must be warmed to at least +10°C and inverted three times before use to ensure proper mixing.
Storage position: Cylinders should be stored upright (vertical position) whenever possible. If stored horizontally, they must be placed on a flat surface and secured to prevent rolling. Before use, cylinders stored horizontally should be stood upright for at least 48 hours or inverted three times to ensure mixing.
General storage requirements include keeping cylinders in a well-ventilated area away from direct heat sources, combustible materials, and open flames. Although Kalinox is not flammable itself, nitrous oxide supports combustion vigorously — it is a strong oxidizer. Cylinders should be secured to prevent falling, kept away from oils and greases (which can ignite on contact with oxygen under pressure), and stored separately from other compressed gases according to local regulations.
Shelf life: The shelf life of Kalinox varies by manufacturer but is typically 3-5 years from the date of manufacture when stored properly. Check the expiry date on the cylinder label before use. Expired cylinders must not be used and should be returned to the supplier for disposal or refilling. Partially used cylinders can be stored for future use within their expiry date.
What Does Kalinox Contain?
Kalinox is unique among pharmaceutical products in that it contains only two active gaseous ingredients with no excipients, preservatives, or inactive ingredients. This simplicity reduces the risk of allergic reactions and means there are essentially no concerns about inactive ingredient sensitivities that apply to many other medications.
Active Ingredients
| Ingredient | Chemical Formula | Concentration | Role |
|---|---|---|---|
| Nitrous oxide | N2O | 50% v/v | Provides analgesia and anxiolysis |
| Oxygen | O2 | 50% v/v | Maintains adequate tissue oxygenation; prevents hypoxia |
Cylinder identification: Kalinox is supplied in high-pressure cylinders that are color-coded according to international standards. The cylinder body is typically blue (indicating nitrous oxide content) with a blue and white shoulder (indicating the premixed N2O/O2 combination), though exact coloring may vary by country. The cylinder pin-index system and valve connections are specifically designed to prevent connection to wrong gas delivery systems, providing an additional layer of safety against accidental misuse.
Cylinder pressure: At 15°C, the cylinder pressure is approximately 137 bar (1,987 psi). The cylinder contains the gases in a mixture where nitrous oxide exists partly in liquid phase and partly in gas phase at pressures above approximately 40 bar. As gas is withdrawn, the liquid nitrous oxide evaporates to maintain the correct 50/50 ratio until the liquid is exhausted, after which the cylinder pressure drops rapidly.
Delivery systems: Kalinox is administered through specialized delivery systems that include a pressure regulator, a demand valve (which only releases gas when the patient inhales), and a patient interface (facemask or mouthpiece). Some systems also include a scavenging attachment to capture exhaled gas, reducing environmental contamination and occupational exposure. The delivery system components are medical devices that must be regularly maintained, cleaned, and inspected to ensure proper function and patient safety.
Frequently Asked Questions About Kalinox
Kalinox is a premixed medicinal gas containing 50% nitrous oxide and 50% oxygen, used for short-term pain relief and anxiety reduction during medical procedures. It is commonly used during wound care, minor surgical procedures, dental treatments, labor and delivery, fracture reduction, burn dressing changes, and diagnostic procedures such as biopsies or lumbar punctures. It provides rapid-onset analgesia within 3-5 minutes and wears off within 5 minutes after stopping inhalation.
Kalinox contains nitrous oxide, which is commonly known as "laughing gas." However, Kalinox is specifically a pharmaceutical-grade premixed gas containing exactly 50% nitrous oxide and 50% oxygen. This equimolar mixture is designed to provide effective pain relief while maintaining safe oxygen levels throughout the procedure. The fixed 50/50 ratio is a key safety feature that distinguishes medical-grade nitrous oxide products from pure nitrous oxide used in other settings.
Yes, Kalinox is widely used in pediatric medicine and is considered safe for children who can understand and follow instructions for using the inhalation mask or mouthpiece. The self-administration feature acts as a built-in safety mechanism: if a child becomes too sedated, they release the mask and the effect wears off rapidly. Kalinox is particularly valuable in pediatric emergency departments for painful procedures such as fracture reduction, wound suturing, and burn dressing changes. It is generally not recommended for children under 1 year of age.
The most common side effects of Kalinox include dizziness, light-headedness, euphoria, nausea, and vomiting. These effects are generally mild and resolve within minutes of stopping the gas. Less common side effects include headache, tingling sensations (paresthesia), altered perception, and drowsiness. Serious adverse effects are rare with short-term use but prolonged or repeated exposure can lead to vitamin B12 deficiency and neurological complications. All side effects typically resolve rapidly once inhalation is discontinued.
The analgesic effect of Kalinox begins within 3-5 minutes of starting inhalation and is maintained throughout continuous breathing of the gas. Once inhalation is stopped, the effect wears off very rapidly — typically within 5 minutes. This rapid onset and offset is one of the key advantages of Kalinox, as it allows patients to recover quickly and resume normal activities shortly after the procedure. There is no prolonged sedation or need for extended monitoring compared to many other sedation methods.
Yes, Kalinox (nitrous oxide/oxygen 50%/50%) has been widely used for labor pain management for decades in many countries, particularly in the UK, Australia, and Scandinavian countries. The birthing person self-administers the gas through a mouthpiece or mask, inhaling during contractions. It provides moderate pain relief and reduces anxiety without affecting uterine contractions. It does not affect the baby and has no lasting sedative effects on the mother. However, it may not provide sufficient pain relief for all patients, and it can be used in combination with other pain management approaches.
References
- European Medicines Agency (EMA). Kalinox Summary of Product Characteristics (SmPC). Last updated 2025.
- Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog. 2008;55(4):124-131. doi:10.2344/0003-3006-55.4.124
- Faddy SC, Garlick SR. A systematic review of the safety of analgesia with 50% nitrous oxide: can lay responders use analgesic gases in the prehospital setting? Emerg Med J. 2005;22(12):901-908. doi:10.1136/emj.2004.020891
- Ducassé JL, Siksik G, Durand-Bechu M, et al. Nitrous oxide for early analgesia in the emergency setting: a randomized, double-blind multicenter prehospital trial. Acad Emerg Med. 2013;20(2):178-184. doi:10.1111/acem.12072
- Tobias JD. Applications of nitrous oxide for procedural sedation in the pediatric population. Pediatr Emerg Care. 2013;29(2):245-265. doi:10.1097/PEC.0b013e318280d824
- National Institute for Health and Care Excellence (NICE). Procedural sedation in children and young people. Clinical Guideline NG40. Updated 2024.
- European Society of Anaesthesiology and Intensive Care (ESAIC). Guidelines on procedural sedation and analgesia in adults. 2023.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List (2023). Geneva: WHO; 2023.
- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707-722. doi:10.1097/ALN.0b013e3181870a17
- Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. Am J Obstet Gynecol. 2002;186(5):S110-S126. doi:10.1067/mob.2002.121259
- British National Formulary (BNF). Nitrous oxide. Last updated January 2026.
Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Anesthesiology, Pain Medicine, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent review according to EMA, FDA, and WHO guidelines
Evidence Standard
Level 1A — Systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
Update Frequency
Content reviewed quarterly and updated when new evidence or guideline changes emerge
This article was written by licensed medical professionals and reviewed independently by the iMedic Medical Review Board. No pharmaceutical funding was involved. For questions about our editorial process, visit our Editorial Standards page.